OBI Entered into an Exclusive License Agreement with Odeon for OBI-999 and OBI-833 to Treat Cancer in China, Hong Kong and Macau
Shots:
- OBI to receive $12M as an equity equivalent upon signing & ~$188M as development & commercialization milestones along with royalties & also obtains global rights to OBI-999 & OBI-833 (Ex- China, Hong Kong & Macao)
- Odeon gets exclusive rights to develop & commercialize OBI-999 & OBI-833 for cancer in China, Hong Kong & Macao & will lead all development, regulatory & commercialization costs of OBI-999 & OBI-833
- In the P-I study, OBI-999 showed an excellent safety & PK profile while OBI-833 also showed a favorable safety profile & generated detectable anti-Globo H IgM and IgG responses along with durable stable disease status for NSCLC patients co-treated with an EGFR-TKI
Ref: PR Newswire | Image: The Pharma Letter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
